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Use of lentiviral Particles as a cell 
Membrane-Based mFasl Delivery 
system for In Vivo Treatment of 
inflammatory arthritis
José M. Rodríguez-Frade1, Anabel Guedán1, Pilar Lucas1, Laura Martínez-Muñoz1, 
Ricardo Villares1, Gabriel Criado2, Dimitri Balomenos1, Hugh T. Reyburn1 and 
Mario Mellado1*
1 Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain, 2 Inflammatory and 
Autoimmune Diseases Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
During budding, lentiviral particles (LVP) incorporate cell membrane proteins in the 
viral envelope. We explored the possibility of harnessing this process to generate LVP-
expressing membrane proteins of therapeutic interest and studied the potential of these 
tools to treat different pathologies. Fas-mediated apoptosis is central to the maintenance 
of T cell homeostasis and prevention of autoimmune processes. We prepared LVP that 
express murine FasL on their surface. Our data indicate that mFasL-bearing LVP induce 
caspase 3 and 9 processing, cytochrome C release, and significantly more cell death 
than control LVP in vitro. This cytotoxicity is blocked by the caspase inhibitor Z-VAD. 
Analysis of the application of these reagents for the treatment of inflammatory arthritis 
in vivo suggests that FasL-expressing LVP could be useful for therapy in autoimmune 
diseases such as rheumatoid arthritis, where there is an excess of Fas-expressing acti-
vated T cells in the joint. LVP could be a vehicle not only for mFasL but also for other 
membrane-bound proteins that maintain their native conformation and might mediate 
biological activities.
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inTrODUcTiOn
Lentiviral vectors are very widely used in biological research, functional genomics, and gene therapy 
since they can mediate gene transfer into dividing and non-dividing cells both ex vivo and in vivo. 
Several examples of their use to correct genetic defects in have been described in both human 
disease (1–3) and animal models (4–7). Lentiviral particles (LVP) are generated through transient 
transfection of three plasmids in the human embryonal kidney (HEK293T) cells, a packaging, a 
transfer, and an envelope-encoding plasmid (8). As the LVP bud from the cell, membrane frag-
ments bearing cellular proteins are incorporated into the LVP. For example, we found that CXCR4 is 
incorporated into virions that can be easily purified and maintain the ability to bind CXCL12 with 
native affinity (9). It has also been observed that several other chemokine receptors, when expressed 
in retroviral particles, can still bind antibodies and HIV-gp120 Env specifically (10), demonstrat-
ing the correct folding of these receptors in the LVP. Here, we addressed the hypothesis that the 
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controlled incorporation of specific membrane glycoproteins into 
LVP could be utilized to generate nanoparticles able to modulate 
immune system function.
The Fas (CD95)/FasL (CD178) receptor/ligand interaction is 
a key factor in the induction of programmed cell death (11). Fas/
FasL belong to the tumor necrosis factor (TNF)/TNF receptor 
(TNFR) family (12) and, like other members of the TNF family, 
biologically active FasL is a trimer (13). A FasL trimer recruits 
three Fas molecules, resulting in oligomerization of an intracellu-
lar death-inducing signaling complex (14) that through a cascade 
of several caspases triggers programmed cell death (11). This 
pathway is active during CTL-mediated killing of virus-infected 
or cancer cells (15) and in suppression/regulation of activated 
effector T cells (16, 17), among other processes. Fas-mutant (lpr) 
and FasL-deficient (gld) mice suffer autoimmune pathology due 
to dysregulated lymphoproliferative processes, indicating the 
relevance of this mechanism in the regulation of immune system 
homeostasis (18, 19).
Fas expression is observed in a variety of immune and non-
immune cells (19), whereas FasL at the cell membrane (mFasL) 
is expressed by CD8+ cytotoxic T  cells as well as a proportion 
of activated CD4+ T cells and NK cells. mFasL is processed by 
metalloproteases to generate soluble FasL (sFasL) that although 
still able to bind Fas, is much less efficient in killing target cells 
(20), consistent with the idea that clustering of preassembled Fas 
trimers is required for optimal apoptosis induction (21).
Here, we generated non-infectious lentiviral expressing 
murine FasL (FasL-LVP) and tested their efficiency in specific 
killing of Fas-expressing cells. Exposure of Fas-expressing cells 
to the FasL-LVP triggered activation of caspase 3 and subsequent 
apoptosis, as shown by annexin V (AV)-propidium iodide (PI) 
incorporation and cell cycle analysis, with no crosslinking 
requirement. FasL-LVP injection in the footpad of mice with 
established collagen-induced arthritis caused a reduction in 
paw inflammation, of cells infiltrating the tissue, as well as 
clear improvement in the clinical score compared to controls. 
Our in vitro and in vivo results indicate that administration of 
non-infective, non-replicative LVP expressing FasL could be a 
novel method for local treatment of inflammatory diseases. This 
pharmaceutical formulation avoids the requirements for FasL 
purification that might affect its conformation and/or activity 
and reduces side effects due to crosslinking requirements with 
anti-FasL antibodies.
MaTerials anD MeThODs
cells
HEK293T cells (human embryonic kidney cells) were obtained 
from American Type Culture Collection (ATCC CRL-11268, 
UK). The IL-3-dependent murine pro-B  cell line, BaF/3, was 
obtained from German Collection of Microorganisms and 
Cell Cultures (DSMZ ACC300, Germany), and the murine 
pre-B lymphoma cell line L1.2 (22) was cultured in RPMI 1640 
medium (BioWhittaker) supplemented with 10% FCS, 2  mM 
l-glutamine; for BaF/3, 10% conditioned medium of an IL-3-
producing WEHI-3B  cell line (DSMZ ACC26) was added to 
medium.
Thymus tissue from C57BL/6 mice (Harlan Laboratories, 
Inc., USA) was disaggregated with a potter homogenizer and the 
isolated thymocytes cultured in RPMI, 50 µM β-mercaptoethanol 
and 10 mM HEPES (pH 7.4). All cells were maintained at 37°C 
with 5% CO2.
generation of gPi-linked Fasl (Fasl-gPi) 
constructs
To prepare the construct encoding murine FasL attached 
to the membrane via a glycosylphosphatidylinositol 
(GPI) anchor the following oligonucleotides: mFasLFor—
AGAGTCGACGCCACCATGCAGCAGCCCATGAATTAC; 
mFasLRev—GCAAGC TTAGAGCTTATACAAGCCGAAAA 
AGG; FasLFor—AGAGTCGACGCCACC ATGCTGGGCATC 
TGGACCCTCCTACCTCTGGTTCTTACGTCTGTTGCTAC 
ACCCTC; mFasLGPIFor—ACGTCTGTTGCTACACCCTCTG 
AAAAAAAAGAGC; and mFasLGPIRev—GCAAGCTTGCCA 
CCAGAGCTTGAACTGAGCTTATACAAGCC GAAAAAGG. 
 DAFGPIFor—GCAAGCTTCCAAATAAAGGAAGTGGAACC; 
DAFGPIRev—GCATGCGGCCGCTAAGTCAGCAAGCCC 
ATGGTTAC were used to amplify fragments of mFasL, murine 
DAF, and a linker sequence from mouse spleen cDNA, and then 
different combinations of these oligonucleotides were used to 
amplify overlapping fragments from the first round of PCR to 
generate a full length mFasL-GPI fragment that was cloned into 
the pBJ-Neo vector (23).
generation of lVP
Lentiviral expressing murine FasL (FasL-LVP) were produced 
by transient co-transfection of HEK293T  cells with mFasL-
GPI-LVTHM/GFP plasmid and, 24 h later, with PAX2 plasmid 
(Tronolab, Switzerland) at a 1:1 ratio using JetPEI (Polyplus-
transfection; Illkirch, France). At 72  h posttransfection, cell 
supernatant was collected and centrifuged (30  min, 350  ×  g, 
RT) followed by ultracentrifugation in a Beckman SW55 rotor 
(2 h, 46,000 × g, 4°C) through a 20% sucrose cushion. The LVP-
containing pellet was concentrated, resuspended in PBS, and 
stored in aliquots at −80°C. Control LVP were produced as above 
using HEK293T cells transfected with empty LVTHM/GFP and 
PAX2 plasmids (control HEK293T cells).
Flow cytometry analysis
For cell staining, cells were incubated (3 ×  105  cells/well) with 
appropriate antibodies diluted in 50 µl staining buffer (PBS, 5% 
FCS, 1% BSA, 5  mM EDTA). After incubation (30  min, 4°C), 
cells were washed twice with staining buffer and analyzed in a 
Gallios cytometer (Beckman Coulter, CA, USA). Experiments 
were analyzed using FlowJo software (FlowJo, OR, USA).
Antibodies used include anti-mCD95-PE (BD Biosciences, 
CA, USA), -mCD95L-PE (BD Biosciences), and -CXCR4-biotin 
(R&D Systems, MN, USA). Streptavidin PE was from Beckman 
Coulter.
attachment of lVP to latex Beads
To evaluate FasL-expressing LVP, we used flow cytometry of LVP 
coupled to latex beads. Aldehyde/sulfate latex beads (4 µm, 4% 
w/v; A37304, Invitrogen, ThermoFisher Scientific, MA, USA) 
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were sonicated (5 min, RT) and mixed in a 1:3 v/v ratio with LVP 
(15 min, RT). PBS (1 ml) was added, and the final suspension was 
incubated (60 min, 4°C) with continuous rocking. Free reactive 
groups were blocked using glycine (100  µl, 1  M, 30  min, RT). 
Beads coupled to LVP were washed with PBS/BSA 0.5%. For 
FACS analysis, the pellet was resuspended in PBS staining buffer 
and stained with specific antibodies as described above.
cell cycle analysis
Thymocytes or BaF/3 cells (5 × 105) were incubated (37°C, 5% 
CO2) with 10 µg/ml control LVP or FasL-LVP (6 h, 37°C). After 
washing with PBS, cells were resuspended in 50  µl detergent 
(DNA-Prep Reagent Kit, Beckman Coulter) containing 10 ng/ml 
PI (DNA-Prep Reagent Kit; 30 min, 37°C). Cell cycle phases were 
analyzed by flow cytometry. sFasL (2 µg/ml; Peprotech, NJ, USA) 
crosslinked with anti-6-His antibody (10 µg/ml, Sigma) was used 
as control.
aV-Pi incorporation
Thymocytes, BaF/3, or L1.2 cells (5 × 105) were incubated (37°C, 
5% CO2) with 10 µg/ml control LVP or FasL-LVP (at different 
time points, 37°C). Cells were stained with AV-FITC and with 
PI following the manufacturer protocols (Aposcreen Annexin 
V apoptosis kit-FITC; Southern Biotech, AL, USA). All samples 
were analyzed in a Gallios cytometer. The number of early apop-
totic (AV+/PI−) and necrotic/late apoptotic (AV+/PI+) cells was 
expressed as a percentage of total cells.
Western Blot
Cells were lysed in 100 µl lysis buffer containing triethanolamine 
(20 mM, pH 8) and 2% digitonin, supplemented with protease 
inhibitors, aprotinin and leupeptin (20  µg/ml each), PMSF 
(1 mM), and sodium orthovanadate (10 µM). Lysis was carried 
out with agitation (30 min, 4°C). After centrifugation (15 min, 
24,000 × g, 4°C), protein concentration in lysates was determined 
using BCA (Pierce, IL, USA). Thymocyte lysates (40 µg) and LVP 
(10, 20, and 40 µl) were resolved by 12% SDS-PAGE, transferred 
to nitrocellulose membrane (Bio-Rad, CA), blocked with 5% 
dry milk in TBS (60  min, RT, rocking), and incubated (ON, 
4°C) with primary antibodies: anti-mFasL (BD Biosciences), 
-caspase 8 (Alexis, Switzerland), -caspase 3 (Cell Signaling, MA, 
USA), or -GFP (Invitrogen, CA, USA). After incubation with 
appropriate peroxidase (PO)-conjugated secondary antibody 
(Dako, Denmark), proteins of interest were detected by chemi-
luminescence (ECL, Pierce, IL, USA). ImageJ software was used 
for quantitation.
immunofluorescence
Cells were incubated with Mitotracker (250  nM, 30  min, 
37°C, MitoTracker Green FM, ThermoFisher) and seeded 
(1.5 × 105 cells, 30 min, 37°C) on microscope slides coated with 
poly-l-lysine (20  µg/ml, ON, 4°C, Sigma-Aldrich). Cells were 
fixed (PFA 4%, 10 min RT, Sigma-Aldrich), permeabilized (0.2% 
Triton X-100 in PBS, 10  min, RT), and blocked with blocking 
buffer (PBS, 1% BSA, 0.1% goat serum, 0.05% T20, 30 min, RT). 
Anti-cytochrome C antibody was added (1:200 dilution in block-
ing buffer, 45 min, RT, AbCam) followed by anti-mouse Alexa 647 
(1:500 dilution in blocking buffer, 45 min, RT, Molecular Probes). 
After extensive washing with PBS, samples were incubated with 
DAPI (1:100, 20  min, RT, Sigma-Aldrich) and analyzed in an 
Olympus FV1000 confocal microscope with a 63× NA 1.4 oil 
objective.
induction and assessment of cia
Two-month-old DBA/1J mice were immunized intradermally at 
the tail base with an emulsion of chicken type II collagen (CII) 
in Freund’s complete adjuvant (24). Arthritis was assessed daily 
by scoring each limb on a 0–4 scale, where 0 = normal, 1 = ery-
thema and mild swelling confined to the tarsals or ankle joint, 
2 = erythema and mild swelling extending from the ankle to the 
tarsals, 3 = erythema and moderate swelling extending from the 
ankle to metatarsal joints, and 4 = erythema and severe swelling 
encompass the ankle, foot and digits, or ankylosis of the limb, 
yielding a maximum score of 16 per mouse. Limbs with a score 
>2 (Cs0) were inoculated on day 0, 2, 4, 6, and 9 in the footpad 
with FasL-LVP or LVP (30 µg/ml, 50 µl) and the clinical score 
re-evaluated (Cst). As control, unaffected limbs were treated in 
parallel with FasL-LVP or LVP (30 µg/ml, 50 µl).
At the end of the experiment, the score was monitored, and 
the paws were removed, fixed in 4% formalin, decalcified with 
10% EDTA, and paraffin-embedded. Sections (4 µm thick) were 
stained with hematoxylin and eosin or alkaline phosphatase.
enzyme-linked immunoassay
Microtiter plates were coated with chicken type II collagen 
(5 µg/ml; 90 min, 37°C). After blockade of remaining protein-
binding sites with 0.5% BSA in PBS, plates were incubated with 
serial dilutions of serum samples of immunized DBA/1J mice, 
followed by PO-labeled subclass-specific rabbit anti-mouse 
antisera. When needed, LVP- and FasL-LVP-coated microtiter 
plates (1 µg/ml) were incubated with serial dilutions of serum 
samples of mice injected with LVP in the footpad (time 0 and 
14 days after treatment), followed by PO-rabbit anti-mouse IgG 
(Dako) antisera.
statistical analysis
Results were analyzed with Prism 5.0 (GraphPad Software; 
***p < 0.0001, **p < 0.001, *p < 0.05). We used one-way ANOVA 
analysis and Tukey’s multiple comparison test. Data are shown as 
mean ± SEM.
resUlTs
lVP express Fasl at the Particle surface
We transiently transfected HEK293T cells with PAX2, pGEM-
GFP and FasL-GPI-LVTHM/GFP-murine, or empty LVTHM/
GFP plasmids (control). Transfection efficiency was controlled 
by assessing GFP expression via fluorescence microscopy, 
Western blot and flow cytometry, whereas flow cytometry 
and Western blot analysis using anti-FasL mAb confirmed 
specific expression of FasL in cells transfected with FasL-
GPI-LVTHM/GFP (Figures  1A,B). Flow cytometry analysis 
of LVP, isolated by centrifugation through a sucrose pellet, 
using specific mAb showed that FasL could be detected on the 
FigUre 1 | continued  
Fasl expression at the surface of lentiviral particles (lVP). 
(a) HEK293T cells transfected with GPI-linked FasL or control plasmid were 
analyzed by fluorescence microscopy and Western blot and (B) by flow 
cytometry using specific anti-mFasL antibodies. GFP expression was 
analyzed as a control of cell transfection. One experiment is shown of five 
performed. The gray bell-shaped curve indicates detection in untransfected 
HEK293T cells. (c) Flow cytometry analysis of control and mFasL expression 
in LVP coupled to latex beads. A representative experiment is shown of five 
performed. (D) Western blot analysis of mFasL- and control LVP using 
specific anti-GFP and -mFasL antibodies. A representative experiment is 
shown of more than five performed.
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surface of LVP obtained from cells transfected with FasL-GPI 
(FasL-LVP) (Figure 1C, lower panel), but not on LVP obtained 
from HEK293T  cells transfected with a control vector (LVP) 
(Figure  1C, upper panel). Both types of particles (FasL-LVP 
and LVP) expressed similar levels of CXCR4, a receptor 
endogenously expressed by HEK293T  cells (Figure  1C). To 
confirm FasL expression, detergent extracts of FasL-LVP and 
LVP were evaluated by Western blot using specific anti-FasL 
mAb (Figure 1D, upper panel). GFP expression in FasL-LVP 
and control LVP was analyzed as a loading control and was also 
used to normalize the number of control and FasL-LVP used in 
subsequent assays (Figure 1D, lower panel).
mFasl-lVP are Fully Functional In Vitro
Ba/F3 cells constitutively express Fas at the cell surface, which 
can be upregulated by IL-3 treatment (25) (Figure 2A, left). To 
test the ability of FasL-LVP to trigger cell apoptosis, Ba/F3 cells 
(106 cells/ml) were plated in RPMI medium supplemented with 
5% FCS and IL-3, and exposed to serial dilutions of FasL-LVP, 
control LVP, or sFasL plus crosslinker as a positive control. Cell 
cycle analysis by PI incorporation and flow cytometry showed 
that treatment with FasL-LVP significantly increased cell death 
compared to control (Figure 2B).
To test whether FasL-LVP treatment could also induce the 
death of primary cells, we used thymocytes, as they also express 
Fas at the cell surface (Figure  2A, right). Thymocytes isolated 
from 3-month-old C57BL/6 mice were treated with different 
amounts of FasL-LVP, LVP, or sFasL plus crosslinker for vari-
ous times (2, 4, 6, 8, or 24 h) and analyzed as above. FasL-LVP 
significantly increased cell death compared to control LVP, with 
a maximum effect after 6 h treatment (Figure 2C). Pretreatment 
of cells with the pan-caspase inhibitor Z-VAD (R&D) blocked 
FasL-LVP-mediated apoptosis (Figure  2C), suggesting caspase 
involvement in the cell death process activated by exposure to 
FasL-LVP.
These results were confirmed by determining AV-PI incor-
poration in thymocytes, and Ba/F3 cells treated with FasL-LVP 
or control LVP. As an additional control of specificity, FasL-LVP 
did not trigger apoptosis of L1.2 cells (Figure 2D). Murine pre-B 
L1.2 cells do not express Fas at the cell surface, as shown by flow 
cytometry with anti-mCD95-PE mAb (Figure 2A).
FasL binding to Fas receptor leads to the formation of the 
DISC (death-inducing signaling complex), autoprocessing 
of the initiator procaspase 8 and activation of the effector 
FigUre 1 | continued
FigUre 2 | Fasl-lVP mediated induction of cell death. (a) Flow cytometry analysis of Fas (CD95) expression in BaF/3; L1.2 cells and murine thymocytes. 
An experiment is shown of three performed. (B) Cell cycle analysis using propidium iodide (PI) incorporation and flow cytometry analysis of BaF/3 cells treated 
with crosslinked soluble FasL (sFasL), mFasL, and control lentiviral particles (LVP) for 6 h. Gates defining the different cell cycle phases are indicated. The figure 
shows one experiment of more than five performed. The percentages of cells in each cell cycle phase as well as those for cell apoptosis are shown. (c) Cell 
cycle analysis using PI incorporation and flow cytometry analysis of murine thymocytes, untreated or pretreated with Z-VAD and untreated or treated with 
crosslinked sFasL, mFasL, or control LVP for 6 h. The figure shows the percentage of apoptotic cells; data are shown as mean ± SD of six independent 
experiments (***p < 0.0001). (D) Apoptosis of murine thymocytes, BaF/3, and L1.2 cells treated with FasL- or control LVP (4 h). The number of early apoptotic 
(AV+/PI−) and necrotic/late apoptotic (AV+/PI+) cells was expressed as a percentage of total cells. Results of three independent experiments are shown as 
mean ± SD (***p < 0.0001).
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FigUre 3 | induction of caspase processing and cytochrome 
c release by Fasl-lVP. (a) Western blot analysis of caspase 3 processing 
in murine thymocytes, alone or pretreated with Z-VAD and untreated or 
treated with crosslinked soluble FasL (sasL), FasL- and control lentiviral 
particles (LVP) for 6 h, using specific antibodies. An experiment is shown of 
three performed. (B). Western blot of caspase 9 processing in murine 
thymocytes as in panel (a). An experiment is shown of three performed. 
(c) Immunofluorescence analysis of cytochrome c release using specific 
antibodies and murine thymocytes treated with FasL- or control LVP for 6 h. 
One experiment is shown of five performed.
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procaspase-3, which triggers the extrinsic pathway of apoptosis 
(26) and/or cytochrome C release from mitochondria and cas-
pase 9 activation (intrinsic pathway). Processing of procaspase 
8 was not detected in any of these experiments (not shown); 
nevertheless, exposure to FasL-LVP specifically induced 
cleavage of caspase 3 in thymocytes incubated for 6  h with 
FasL-LVP (Figure 3A). FasL-LVP-induced cleavage of caspase 
3 was blocked when thymocytes were pretreated with the pan-
caspase inhibitor Z-VAD (Figure 3A), indicating the specificity 
of the effect. Cleavage of caspase 9 was also observed in these 
experiments (Figure  3B). Moreover, rapid, specific release 
of cytochrome C, indicative of mitochondrial damage, was 
detected when thymocytes were treated with FasL-LVP, but not 
LVP controls (Figure 3C). Overall, these data showing involve-
ment of both caspases 3 and 9 and mitochondrial damage in 
the cell death of thymocytes treated with FasL-LVP suggests 
that exposure to these particles triggers both the extrinsic and 
intrinsic pathways of apoptosis.
local administration of Fasl-lVP reduces 
Paw swelling in a Murine Model of 
arthritis
The collagen-induced arthritis model in DBA/1J mice was used to 
assess the potential therapeutic utility of FasL-LVP administration, 
since Fas expression is enhanced on activated lymphocytes and 
the immunopathogenesis in this model involves both T-cell and 
B-cell-specific responses to collagen (27). Arthritis was induced 
by subcutaneous injection of collagen type 2 into 2-month-old 
DBA/1J mice. On appearance of the first signs of CIA (score ≥2, 
day 0), arthritic mice received four injections on days 0, 2, 4, and 
6 of either FasL-LVP or LVP (30 µg/ml, 50 µl) in the inflamed 
paw (left or right limbs, respectively). While disease progressed 
in LVP-treated mice, a clear reduction in paw swelling (p < 0.01) 
(Figure  4A) was observed in FasL-LVP-treated animals. This 
effect was observed as early as 2 days after initiation of treatment 
and reached maximum at 14  days after the initial inoculation. 
Treatment with neither FasL-LVP nor LVP promoted any 
changes in non-inflamed paws. The reduced severity of disease in 
FasL-LVP-treated mice was not associated with changes in anti-
collagen type II antibody levels (Figure 4B), suggesting that the 
effect is confined mainly to the administration site. Histological 
analysis of paws from both FasL-LVP- and LVP-treated mice 
showed that the inflammation and pannus parameters differed 
clearly between these groups. Similarly, the damage observed in 
cartilage and bone in control mice was absent in those treated 
with FasL-LVP (Figure 4C). We nonetheless detected a small but 
sustained immune response to LVP in treated mice (Figure 4D). 
The use of the human HEK293T  cell line to prepare the LVP 
might underlie this side effect.
DiscUssiOn
As they bud from the membrane of the cell, LVP incorporate 
components of the plasma membrane, including embedded pro-
teins in their lipid environment, into the virus particle (28). Here, 
we show that this property can be exploited to develop virus-like 
particles that can subsequently modulate cell activation both 
in vitro and in vivo.
The Fas molecule belongs to a subset of the TNFR family 
called death receptors, which can trigger apoptosis by inducing 
caspase activation. Ligation of Fas triggers apoptosis in activated 
T  cells; this mechanism is involved, for example, in regulation 
of the clonally expanded T  cell population after antigen clear-
ance (11). Fas-mediated apoptosis can also be activated in other, 
non-immune, cell types including the death of neurons after 
withdrawal of growth factors, of fibroblasts expressing c-Myc, of 
thyroid cells and even of endothelial cells (29–32), which suggests 
that Fas can be considered a target for therapeutic intervention 
in several diseases.
We engineered and transiently expressed a chimeric FasL-GPI 
in HEK293T cells and used them to produce LVP that express 
FasL, but lack viral envelope proteins. Replacement of C-terminal 
transmembrane domains by GPI-addition signal peptides allows 
expression of the proteins on the plasma membrane and provides 
stable association of the construct with the lipid bilayer (33, 34). 
FigUre 4 | effect of local administration of Fasl-lVP in a murine model of arthritis. (a) Evolution of the paw swelling score after treatment with FasL- or 
control LVP (Cst), expressed as a percentage of the initial score (Cs0) (n = 12; **p < 0.001, *p < 0.05). (B) Levels of total anti-collagen II IgG (micrograms per milliliter) 
were measured in mouse sera by ELISA at the end of the experiment (day 14 posttreatment). (c). Eosin–thiazin staining of representative sections of ankle joints of 
the mice in panel (a) at day 14 posttreatment with lentiviral particles (LVP) (left) or FasL-LVP (right). The figure shows decreased cell infiltration (a), bone erosion (b), 
and cartilage destruction (c) in FasL-LVP-treated mice. Original magnification 10×. (D) Levels of total anti-LVP IgG were measured in mouse sera by ELISA on days 0 
and 14 after LVP and FasL-LVP treatments.
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Plasmids encoding viral envelope proteins, i.e., VSV-G (glyco-
protein of the vesicular stomatitis virus), were not used in the 
viral particle preparation since VSV-G expression facilitates virus 
dissemination, promoting a range of non-specific changes that 
could obscure the specific effects of treatment with FasL (35).
In vitro, the virus-like particles induced cell death in Fas-
positive cells, including the B cell line, BAF/3 and primary thymo-
cytes. The absence of apoptosis in L1.2 cells, which do not express 
cell surface Fas, and in cells treated with control LVP showed 
that this effect is specific; it indicated that FasL-LVP-induced 
cell death is mediated by the FasL expressed on the particles and 
not by other components expressed at the membrane or by other 
LVP components. In this context, when VSV-G pseudotyped 
LVP were used in similar experiments, increased cell death was 
observed independently of FasL, probably due to the ability of 
these LVP to infect cells (36).
FADD-mediated activation of the proteolytic activity of cas-
pase 8 is essential for Fas-induced apoptosis in many cell types 
(37–39); nonetheless, caspase 8 cleavage was not observed in 
our experiments. We demonstrated processing of caspase 3 and 
caspase 9 as well as cytochrome C release from mitochondria, 
which suggests FasL-mediated activation of both the extrinsic and 
intrinsic apoptosis pathways. It is possible that in our experimen-
tal conditions, modest activation of caspase 8 was undetected; 
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indeed, a Fas signaling pathway involving slowly activated cas-
pase 8 and mitochondrial damage has been reported (40). This 
pathway involves lower levels of activated caspase 8 which are still 
sufficient to process the pro-apoptotic protein Bid. Translocation 
of Bid to the mitochondrial membrane induces oligomerization 
of Bcl-2, Bak, and Bax, which promote cytochrome release and 
finally caspase 9 activation (41). Nevertheless, the possibility of 
FasL-LVP-mediated activation of a caspase 8-independent apop-
tosis mechanism cannot be excluded. Caspase-independent acti-
vation of JNK leading to cell death has been reported (42), as has 
Fas-mediated cell death that is not blocked by specific caspase 8 
inhibitors (43). New experiments are required to clarify this issue. 
Whatever the mechanism, the data presented here clearly show 
that LVP displaying FasL can induce apoptosis in Fas-expressing 
cell lines and primary cells in vitro.
Although apoptotic cells are rarely observed in RA tissues 
in vivo (44), probably due to intra- and extracellular antiapoptotic 
processes (45, 46), high Fas/FasL levels are present in the syn-
ovium of RA patients (44). Since apoptosis induced by anti-Fas 
antibody or by gene transfer of FasL ameliorates arthritis in the 
experimental murine model of collagen-induced arthritis, prob-
ably via the induction of apoptosis of T cells, macrophages, and 
synoviocytes (47–49), we tested the use of our LVP as therapy in 
this model. Local injection of FasL-LVP into the inflamed footpad 
specifically reduced paw inflammation. This effect was restricted 
to the injected paw, as no improvement of inflammation was noted 
in the contralateral hind paw that received the injection of control 
LVP. In addition, no effect was observed on anti-collagen type 
II antibody levels. These data indicate that the injected LVP did 
not disseminate outside the injection site. Histological analysis 
reflected a significant reduction of cell infiltration in joints treated 
with FasL-LVP compared to controls. The simplest interpretation 
of these experiments is that the FasL-LVP induces death of the 
activated (Fas-expressing) lymphocytes and macrophages that 
mediate the autoimmune process. We also detected low anti-LVP 
antibody levels in the sera of treated mice, which indicated that 
LVP treatment might activate a slight immune response to the 
viral particles, which could decrease treatment efficiency. The use 
of human HEK293T cells to generate the LVP for use in a murine 
system might underlie this effect. LVP generation in compatible 
cells should reduce this side effect. LVP have been widely used for 
human gene therapy for many years, and several strategies have 
been developed to avoid, suppress, or manipulate the immune 
response and promote immune tolerance to the LVP (50).
The use of FasL-LVP as a therapeutic strategy has a number of 
advantages compared to the use of sFasL. It is suggested that non-
apoptotic, Fas-mediated signals can promote chronic inflamma-
tory arthritis. For instance, DBA1/lpr mice, which are defective 
in Fas signaling, are less susceptible to CIA (51). Indeed, sFasL is 
increased in synoviocytes of RA patients compared to those suf-
fering from OA, and sFasL levels are higher in patients with severe 
RA compared to those with mild disease, indicating that sFasL 
may be an exacerbating factor in RA (52). sFasL, cleaved from 
cell membranes by metalloproteases, contributes to Fas down-
regulation, thus reducing Fas-mediated apoptosis in RA synovial 
cells and perpetuating the disease (53). The construct used in 
the preparation of FasL-LVP lacks the proteolysis site found in 
membrane FasL, which minimizes the possibility of sFasL pro-
duction. Another advantage of this construct is that the intrinsic 
structure of the FasL displayed on the virus-like particle is likely 
very similar to that on the cell membrane, rendering crosslinking 
with antibodies unnecessary. The use of monoclonal antibodies 
to crosslink sFasL is associated with liver toxicity (54), whereas a 
synthetic human hexameric FasL (APO010, Topotarget) promotes 
human glioma cell death and prolongs survival in tumor-bearing 
mice with no need for crosslinkers (55). In vivo, Fas expression is 
enhanced after lymphocyte activation; we also demonstrated that 
FasL-LVP, presumably by inducing the death of activated cells, 
can be used to treat autoimmunity. Our in vitro and in vivo results 
indicate that the administration of non-infective, non-replicative 
LVP expressing FasL could be a novel method for local treatment 
of inflammatory diseases.
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